Cancer Therapeutics CRC (CTx) is a collaborative partnership of leading research institutes, universities and biotechnology companies which translates Australia’s innovative research discoveries into new cancer drugs ready for clinical development.
CRC offers a wide range of R&D platforms, with technologies to aid researchers from drug discovery to clinical candidates. Capabilities include: high throughput screening (HTS), medicinal chemistry, recombinant protein production, structural biology, translational cancer biology and drug metabolism and pharmacokinetics (DMPK).
Established in 2008, MIPS is a leading centre of pharmaceutical science and houses over 400 researchers and students to undertake basic and translation drug discovery, drug delivery and drug development at Parkville.
The institute is comprised of four fundamental, highly-collaborative research themes which work to translate basic research into clinical trials: Medicinal Chemistry, Drug Discovery Biology, Drug delivery disposition and dynamics (D4) and Centre for Drug Candidate Optimisation (CDCO).
The CDCO is one of the themes at MIPS and and provides collaborative ADME lead optimisation in support of emerging drug discovery programs, with the aim to produce optimised, high quality drug candidate for subsequent pre-clinical and clinical development.
The ATMCF is a purpose-designed, outward-facing collaborative facility to support early stage medicinal chemistry-led drug discovery through collaborations.
ATMCF provides expertise in small molecules hit-to-lead optimisation for increased potency, selectivity and in vivo efficacy. It also provides expertise in high-throughput screening (HTS) hit selection, fragment-based drug discovery (FBDD), structure-based drug design and SAR guided optimisation.
Managed jointly by the University of Auckland and the Cancer Society Auckland, the ACSRC is internationally recognised as a world-leading anticancer drug development laboratory.
The Centre aims to improve cancer therapy via new drug development and understanding cancer biology through close collaborations with researchers and pharmaceutical firms together with its state-of-the-art facilities, and has filed over 100 patent applications with 8 cancer drugs going into clinical trials.